BCR-ABL1 monitoring is more sensitive than LSC phenotyping, and it is not known whether CD25 is an appropriate target for CML therapy due to its potential role as a tumor suppressor in leukemogenesis. This evidence concerns the gene IL2RA and chronic myelogenous leukemia, BCR-ABL1 positive.